Anti-CRISPR/Cas9 (Clone 7A9-3A3)- FITC (C3458-25ug)

The CRISPR/Cas9 system is an RNA-guided endonuclease system used for genome editing that was first identified as an adaptive immune system in bacteria and archaea1. To operate, a single guide RNA is responsible for DNA site targeting, while Cas9 cleaves the DNA at the target sites. Cas9 contains RuvC and HNH nuclease domains, which are responsible for cleaving the target complementary and noncomplementary DNA strands. Cas9 is directed to the specific DNA targets by the single guide RNA. Any DNA sequence that contains the N20-NGG motif can be recognized as a target site. The CRISPR/Cas9 system has been engineered to allow genome editing in a variety of organisms beyond bacteria1. Codon-optimized Cas9 with an appropriate nuclear localization signal has been used in yeast, roundworm, silkworm, Drosophila, zebrafish, frog, rabbit, human, mouse, rat, pig, monkey, and plants. A single gene or multiple genes (e.g., at least four genes in rat, mouse, and zebrafish) can be disrupted by providing the appropriate single guide RNAs and programming the DNA-cleaving activity of Cas9. Large-fragment deletion, inversion, and reporter gene insertion can also be performed. Additionally, methylation effect and chromatin states can be studied using ‘dead’ Cas9, which is a fusion of a non-functional Cas9 with an effector domain. In mouse1, 2, 3 and humans, the CRISPR/Cas9 system has been used to correct genetic diseases (e.g., cystic fibrosis1, sickle cell disease4, and β-thalassemia) and also has applications for cancer treatment5.